Protocol Ledger

NCT05638295 · Phase II · ACTIVE NOT RECRUITING

Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)

Interventional Phase II clinical trial protocol NCT05638295 sponsored by National Cancer Institute (NCI) in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-08-01 Enrollment: 105 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05638295
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)105 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05638295
Protocol FieldVerified Registry Value
NCT IdentifierNCT05638295
Consolidated Lead SponsorNational Cancer Institute (NCI)
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment105 participants (ESTIMATED)
Registered Start Date2024-08-01
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI